Annelien Van Dalem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Annelien Van Dalem has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Bart Keymeulen
Diabetes Research Center, Vrije Universiteit Brussel (VUB), Brussels, Belgium
9 shared publications - Frans K. Gorus
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium
9 shared publications - Daniel Pipeleers
Diabetes Research Center, Vrije Universiteit Brussel (VUB), Brussels, Belgium
8 shared publications - Ilse Weets
Free University Brussels, Brussels, Belgium
7 shared publications Simke Demeester
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium
7 shared publications- Pieter Gillard
Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium
6 shared publications
Latest Publications
- 29 July 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
The severity of harm score database: an evidence-based foundation for laboratory test risk analysis
Background: Patient risk management has become central to clinical laboratory quality standards, including the Clinical and Laboratory Standards Institute (CLSI) EP23 2nd edition (CLSI EP23-ED2), International Organization for Standardization (ISO) 15189:2022, ISO 22367:2026, and ISO 14971:2019. A key component of risk analysis is estimating the severity of harm (SoH) that may result from erroneous laboratory results. We present here the Severity of Harm Evidence Database, a structured, multi-study resource that integrates survey-based SoH assessments from the published independent studies. The database provides ordinal distributions and pooled SoH for 196 unique laboratory tests. Methods: A canonical five-level scale (negligible, minor, serious, critical, catastrophic) was adopted, aligned with ISO 14971:2019. For the 19 tests common to both studies, direct count pooling was performed by summing category-level respondent counts. Wilson score confidence intervals were calculated for all proportions. The database is organized into nine relational sheets and is accompanied by an interactive web application. Results: Out of the 196 tests covered, 19 have pooled estimates from both studies (total n=781 respondents). Pooled analysis confirms that cardiac biomarkers, blood gases, coagulation parameters, electrolytes (potassium, sodium), and therapeutic drug concentrations (digoxin, lithium) consistently receive the highest severity ratings, while certain endocrine markers receive lower scores. Conclusions: The SoH evidence database offers the first publicly available, structured repository of SoH assessments for clinical laboratory tests. It supports compliance with risk management requirements, informs risk-based strategies per CLSI EP23-ED2, and provides an evidence-based foundation for laboratory risk analysis.
- 29 July 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
The severity of harm score database: an evidence-based foundation for laboratory test risk analysis
Background: Patient risk management has become central to clinical laboratory quality standards, including the Clinical and Laboratory Standards Institute (CLSI) EP23 2nd edition (CLSI EP23-ED2), International Organization for Standardization (ISO) 15189:2022, ISO 22367:2026, and ISO 14971:2019. A key component of risk analysis is estimating the severity of harm (SoH) that may result from erroneous laboratory results. We present here the Severity of Harm Evidence Database, a structured, multi-study resource that integrates survey-based SoH assessments from the published independent studies. The database provides ordinal distributions and pooled SoH for 196 unique laboratory tests. Methods: A canonical five-level scale (negligible, minor, serious, critical, catastrophic) was adopted, aligned with ISO 14971:2019. For the 19 tests common to both studies, direct count pooling was performed by summing category-level respondent counts. Wilson score confidence intervals were calculated for all proportions. The database is organized into nine relational sheets and is accompanied by an interactive web application. Results: Out of the 196 tests covered, 19 have pooled estimates from both studies (total n=781 respondents). Pooled analysis confirms that cardiac biomarkers, blood gases, coagulation parameters, electrolytes (potassium, sodium), and therapeutic drug concentrations (digoxin, lithium) consistently receive the highest severity ratings, while certain endocrine markers receive lower scores. Conclusions: The SoH evidence database offers the first publicly available, structured repository of SoH assessments for clinical laboratory tests. It supports compliance with risk management requirements, informs risk-based strategies per CLSI EP23-ED2, and provides an evidence-based foundation for laboratory risk analysis.
- Open Access
- 3 October 2025
- Published by Walter de Gruyter GmbH in Journal of Laboratory Medicine
- Vol. 50 (1) , 55-57
Verification of ferritin on Roche cobas ® 8000 C702 and comparison with E801
- 3 October 2025
- Published by Walter de Gruyter GmbH in Journal of Laboratory Medicine
- Vol. 50 (1) , 55-57
Open AccessVerification of ferritin on Roche cobas ® 8000 C702 and comparison with E801
- 4 February 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (4) , 528-536
Repeated OGTT Versus Continuous Glucose Monitoring for Predicting Development of Stage 3 Type 1 Diabetes: A Longitudinal Analysis
OBJECTIVE: Evidence for using continuous glucose monitoring (CGM) as an alternative to oral glucose tolerance tests (OGTTs) in presymptomatic type 1 diabetes is primarily cross-sectional. We used longitudinal data to compare the diagnostic performance of repeated CGM, HbA1c, and OGTT metrics to predict progression to stage 3 type 1 diabetes. RESEARCH DESIGN AND METHODS: Thirty-four multiple autoantibody-positive first-degree relatives (FDRs) (BMI SD score [SDS] <2) were followed in a multicenter study with semiannual 5-day CGM recordings, HbA1c, and OGTT for a median of 3.5 (interquartile range [IQR] 2.0–7.5) years. Longitudinal patterns were compared based on progression status. Prediction of rapid (<3 years) and overall progression to stage 3 was assessed using receiver operating characteristic (ROC) areas under the curve (AUCs), Kaplan-Meier method, baseline Cox proportional hazards models (concordance), and extended Cox proportional hazards models with time-varying covariates in multiple record data (n = 197 OGTTs and concomitant CGM recordings), adjusted for intraindividual correlations (corrected Akaike information criterion [AICc]). RESULTS: After a median of 40 (IQR 20–91) months, 17 of 34 FDRs (baseline median age 16.6 years) developed stage 3 type 1 diabetes. CGM metrics increased close to onset, paralleling changes in OGTT, both with substantial intra- and interindividual variability. Cross-sectionally, the best OGTT and CGM metrics similarly predicted rapid (ROC AUC = 0.86–0.92) and overall progression (concordance = 0.73–0.78). In longitudinal models, OGTT-derived AUC glucose (AICc = 71) outperformed the best CGM metric (AICc = 75) and HbA1c (AICc = 80) (all P < 0.001). HbA1c complemented repeated CGM metrics (AICc = 68), though OGTT-based multivariable models remained superior (AICc = 59). CONCLUSIONS: In longitudinal models, repeated CGM and HbA1c were nearly as effective as OGTT in predicting stage 3 type 1 diabetes and may be more convenient for long-term clinical monitoring.
- 4 February 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (4) , 528-536
Repeated OGTT Versus Continuous Glucose Monitoring for Predicting Development of Stage 3 Type 1 Diabetes: A Longitudinal Analysis
OBJECTIVE: Evidence for using continuous glucose monitoring (CGM) as an alternative to oral glucose tolerance tests (OGTTs) in presymptomatic type 1 diabetes is primarily cross-sectional. We used longitudinal data to compare the diagnostic performance of repeated CGM, HbA1c, and OGTT metrics to predict progression to stage 3 type 1 diabetes. RESEARCH DESIGN AND METHODS: Thirty-four multiple autoantibody-positive first-degree relatives (FDRs) (BMI SD score [SDS] <2) were followed in a multicenter study with semiannual 5-day CGM recordings, HbA1c, and OGTT for a median of 3.5 (interquartile range [IQR] 2.0–7.5) years. Longitudinal patterns were compared based on progression status. Prediction of rapid (<3 years) and overall progression to stage 3 was assessed using receiver operating characteristic (ROC) areas under the curve (AUCs), Kaplan-Meier method, baseline Cox proportional hazards models (concordance), and extended Cox proportional hazards models with time-varying covariates in multiple record data (n = 197 OGTTs and concomitant CGM recordings), adjusted for intraindividual correlations (corrected Akaike information criterion [AICc]). RESULTS: After a median of 40 (IQR 20–91) months, 17 of 34 FDRs (baseline median age 16.6 years) developed stage 3 type 1 diabetes. CGM metrics increased close to onset, paralleling changes in OGTT, both with substantial intra- and interindividual variability. Cross-sectionally, the best OGTT and CGM metrics similarly predicted rapid (ROC AUC = 0.86–0.92) and overall progression (concordance = 0.73–0.78). In longitudinal models, OGTT-derived AUC glucose (AICc = 71) outperformed the best CGM metric (AICc = 75) and HbA1c (AICc = 80) (all P < 0.001). HbA1c complemented repeated CGM metrics (AICc = 68), though OGTT-based multivariable models remained superior (AICc = 59). CONCLUSIONS: In longitudinal models, repeated CGM and HbA1c were nearly as effective as OGTT in predicting stage 3 type 1 diabetes and may be more convenient for long-term clinical monitoring.
- Open Access
- 25 October 2023
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 205, 110974
Baseline plasma proinsulin response to glucose for predicting therapeutic response to otelixizumab in recent-onset type 1 diabetes
- 25 October 2023
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 205, 110974
Open AccessBaseline plasma proinsulin response to glucose for predicting therapeutic response to otelixizumab in recent-onset type 1 diabetes
- Open Access
- 1 September 2022
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 42 (5) , 566-574
Impact of Bicarbonate Interference on Routine Ion-Selective Electrode Chloride Measurements
Tinne Monteyne, Ph.D., Matthijs Oyaert, Ph.D., Annelien Van Dalem, Ph.D., Maaike Godefroid , Matthias Cuykx, Ph.D., and Nico Callewaert, Ph.D.. Ann Lab Med 2022;42:566-74. https://doi.org/10.3343/alm.2022.42.5.566
- 1 September 2022
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 42 (5) , 566-574
Open AccessImpact of Bicarbonate Interference on Routine Ion-Selective Electrode Chloride Measurements
Tinne Monteyne, Ph.D., Matthijs Oyaert, Ph.D., Annelien Van Dalem, Ph.D., Maaike Godefroid , Matthias Cuykx, Ph.D., and Nico Callewaert, Ph.D.. Ann Lab Med 2022;42:566-74. https://doi.org/10.3343/alm.2022.42.5.566
- Open Access
- 21 May 2019
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 41 (4) , 448-455
Performance evaluation of the prototype Abbott Alinity hq hematology analyzer
Introduction: The analytical and clinical performance as well as the workflow efficiency of the novel, prototype Alinity hq hematology analyzer was evaluated in the clinical laboratory of Universitair Ziekenhuis Brussel, Department of Hematology, Brussels, Belgium.Methods: Within‐run and within‐laboratory imprecision, linearity, and carryover were assessed using clinical blood samples and commercial blood products. Four hundred and seventeen samples were selected for method comparison with Abbott CELL‐DYN Sapphire, and for flagging performance analysis in comparison with smear review and manual microscopic white blood cell (WBC) differential.Results: Within‐run and within‐laboratory imprecision verification demonstrated low %CV for complete blood count and WBC differential results within the normal ranges (0.1%‐10.4%), except for basophil granulocytes. The linearity of the analytical measuring ranges was verified for WBCs, red blood cells, hemoglobin, and platelets. Alinity hq results showed strong agreement with those of CELL‐DYN Sapphire. Good correlation was demonstrated with manual WBC differential results, with negative bias for neutrophil (NEU) granulocytes, and positive bias for lymphocytes and monocytes. Blasts were detected with 75% sensitivity and 96% specificity at 1% blast threshold, and 100% sensitivity at 5% blast threshold. Immature granulocyte detection was more sensitive (81% vs 76%, P = 0.086) and specific (88% vs 78%, P = 0.0002) than with CELL‐DYN Sapphire. Nucleated red blood cell detection was more sensitive (89% vs 63%, P < 0.001) and just slightly less specific (96% vs 99%, P = 0.0067) than with CELL‐DYN Sapphire. Re‐run and reflex testing rates were lower with Alinity hq.Conclusion: The Alinity hq hematology analyzer is suitable for clinical use.
- 21 May 2019
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 41 (4) , 448-455
Open AccessPerformance evaluation of the prototype Abbott Alinity hq hematology analyzer
Introduction: The analytical and clinical performance as well as the workflow efficiency of the novel, prototype Alinity hq hematology analyzer was evaluated in the clinical laboratory of Universitair Ziekenhuis Brussel, Department of Hematology, Brussels, Belgium.Methods: Within‐run and within‐laboratory imprecision, linearity, and carryover were assessed using clinical blood samples and commercial blood products. Four hundred and seventeen samples were selected for method comparison with Abbott CELL‐DYN Sapphire, and for flagging performance analysis in comparison with smear review and manual microscopic white blood cell (WBC) differential.Results: Within‐run and within‐laboratory imprecision verification demonstrated low %CV for complete blood count and WBC differential results within the normal ranges (0.1%‐10.4%), except for basophil granulocytes. The linearity of the analytical measuring ranges was verified for WBCs, red blood cells, hemoglobin, and platelets. Alinity hq results showed strong agreement with those of CELL‐DYN Sapphire. Good correlation was demonstrated with manual WBC differential results, with negative bias for neutrophil (NEU) granulocytes, and positive bias for lymphocytes and monocytes. Blasts were detected with 75% sensitivity and 96% specificity at 1% blast threshold, and 100% sensitivity at 5% blast threshold. Immature granulocyte detection was more sensitive (81% vs 76%, P = 0.086) and specific (88% vs 78%, P = 0.0002) than with CELL‐DYN Sapphire. Nucleated red blood cell detection was more sensitive (89% vs 63%, P < 0.001) and just slightly less specific (96% vs 99%, P = 0.0067) than with CELL‐DYN Sapphire. Re‐run and reflex testing rates were lower with Alinity hq.Conclusion: The Alinity hq hematology analyzer is suitable for clinical use.
- 1 September 2018
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 62 (9)
In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam
We tested the in vitro susceptibility of ceftazidime-avibactam and ceftolozane-tazobactam and 13 other antibiotics against 91 Burkholderia cepacia complex (BCC) strains isolated from cystic fibrosis patients since 2012. The highest susceptibility (82%) was found for trimethoprim-sulfamethoxazole.
- 1 September 2018
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 62 (9)
In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam
We tested the in vitro susceptibility of ceftazidime-avibactam and ceftolozane-tazobactam and 13 other antibiotics against 91 Burkholderia cepacia complex (BCC) strains isolated from cystic fibrosis patients since 2012. The highest susceptibility (82%) was found for trimethoprim-sulfamethoxazole.
- Open Access
- 11 July 2017
- Published by American Diabetes Association in Diabetes Care
- Vol. 40 (8) , 1065-1072
Twenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and HLA-DQ Genotype in a Registry-Based Group of Children and Adults With a First-Degree Relative With Type 1 Diabetes
OBJECTIVE: We investigated whether islet autoantibody profile, HLA-DQ genotype, and age influenced a 20-year progression to diabetes from first autoantibody positivity (autoAb+) in first-degree relatives of patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: Persistently islet autoAb+ siblings and offspring (n = 462) under 40 years of age were followed by the Belgian Diabetes Registry. AutoAbs against insulin (IAA), GAD (GADA), IA-2 antigen (IA-2A), and zinc transporter 8 (ZnT8A) were determined by radiobinding assay. RESULTS: The 20-year progression rate of multiple-autoAb+ relatives (n = 194) was higher than that for single-autoAb+ participants (n = 268) (88% vs. 54%; P < 0.001). Relatives positive for IAA and GADA (n = 54) progressed more slowly than double-autoAb+ individuals carrying IA-2A and/or ZnT8A (n = 38; P = 0.001). In multiple-autoAb+ relatives, Cox regression analysis identified the presence of IA-2A or ZnT8A as the only independent predictors of more rapid progression to diabetes (P < 0.001); in single-autoAb+ relatives, it identified younger age (P < 0.001), HLA-DQ2/DQ8 genotype (P < 0.001), and IAA (P = 0.028) as independent predictors of seroconversion to multiple positivity for autoAbs. In time-dependent Cox regression, younger age (P = 0.042), HLA-DQ2/DQ8 genotype (P = 0.009), and the development of additional autoAbs (P = 0.012) were associated with more rapid progression to diabetes. CONCLUSIONS: In single-autoAb+ relatives, the time to multiple-autoAb positivity increases with age and the absence of IAA and HLA-DQ2/DQ8 genotype. The majority of multiple-autoAb+ individuals progress to diabetes within 20 years; this occurs more rapidly in the presence of IA-2A or ZnT8A, regardless of age, HLA-DQ genotype, and number of autoAbs. These data may help to refine the risk stratification of presymptomatic type 1 diabetes.
- 11 July 2017
- Published by American Diabetes Association in Diabetes Care
- Vol. 40 (8) , 1065-1072
Open AccessTwenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and HLA-DQ Genotype in a Registry-Based Group of Children and Adults With a First-Degree Relative With Type 1 Diabetes
OBJECTIVE: We investigated whether islet autoantibody profile, HLA-DQ genotype, and age influenced a 20-year progression to diabetes from first autoantibody positivity (autoAb+) in first-degree relatives of patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: Persistently islet autoAb+ siblings and offspring (n = 462) under 40 years of age were followed by the Belgian Diabetes Registry. AutoAbs against insulin (IAA), GAD (GADA), IA-2 antigen (IA-2A), and zinc transporter 8 (ZnT8A) were determined by radiobinding assay. RESULTS: The 20-year progression rate of multiple-autoAb+ relatives (n = 194) was higher than that for single-autoAb+ participants (n = 268) (88% vs. 54%; P < 0.001). Relatives positive for IAA and GADA (n = 54) progressed more slowly than double-autoAb+ individuals carrying IA-2A and/or ZnT8A (n = 38; P = 0.001). In multiple-autoAb+ relatives, Cox regression analysis identified the presence of IA-2A or ZnT8A as the only independent predictors of more rapid progression to diabetes (P < 0.001); in single-autoAb+ relatives, it identified younger age (P < 0.001), HLA-DQ2/DQ8 genotype (P < 0.001), and IAA (P = 0.028) as independent predictors of seroconversion to multiple positivity for autoAbs. In time-dependent Cox regression, younger age (P = 0.042), HLA-DQ2/DQ8 genotype (P = 0.009), and the development of additional autoAbs (P = 0.012) were associated with more rapid progression to diabetes. CONCLUSIONS: In single-autoAb+ relatives, the time to multiple-autoAb positivity increases with age and the absence of IAA and HLA-DQ2/DQ8 genotype. The majority of multiple-autoAb+ individuals progress to diabetes within 20 years; this occurs more rapidly in the presence of IA-2A or ZnT8A, regardless of age, HLA-DQ genotype, and number of autoAbs. These data may help to refine the risk stratification of presymptomatic type 1 diabetes.
- Open Access
- 1 June 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (6) , e0179108
Correction: Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio
[This corrects the article DOI: 10.1371/journal.pone.0166702.].
- 1 June 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (6) , e0179108
Open AccessCorrection: Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio
[This corrects the article DOI: 10.1371/journal.pone.0166702.].
- Open Access
- 1 December 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (12) , e0166702
Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio
The hyperglycemic clamp test, the gold standard of beta cell function, predicts impending type 1 diabetes in islet autoantibody-positive individuals, but the latter may benefit from less invasive function tests such as the proinsulin:C-peptide ratio (PI:C). The present study aims to optimize precision of PI:C measurements by automating a dual-label trefoil-type time-resolved fluorescence immunoassay (TT-TRFIA), and to compare its diagnostic performance for predicting type 1 diabetes with that of clamp-derived C-peptide release. Between-day imprecision (n = 20) and split-sample analysis (n = 95) were used to compare TT-TRFIA (AutoDelfia, Perkin-Elmer) with separate methods for proinsulin (in-house TRFIA) and C-peptide (Elecsys, Roche). High-risk multiple autoantibody-positive first-degree relatives (n = 49; age 5–39) were tested for fasting PI:C, HOMA2-IR and hyperglycemic clamp and followed for 20–57 months (interquartile range). TT-TRFIA values for proinsulin, C-peptide and PI:C correlated significantly (r2 = 0.96–0.99; Ps = -0.596; P<0.001) with first-phase C-peptide release during clamp (also with second phase release, only available for age 12–39 years; n = 31), but only after normalization for HOMA2-IR. In ROC- and Cox regression analysis, HOMA2-IR-corrected PI:C predicted 2-year progression to diabetes equally well as clamp-derived C-peptide release. The reproducibility of PI:C benefits from the automated simultaneous determination of both hormones. HOMA2-IR-corrected PI:C may serve as a minimally invasive alternative to the more tedious hyperglycemic clamp test.
- 1 December 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (12) , e0166702
Open AccessPrediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio
The hyperglycemic clamp test, the gold standard of beta cell function, predicts impending type 1 diabetes in islet autoantibody-positive individuals, but the latter may benefit from less invasive function tests such as the proinsulin:C-peptide ratio (PI:C). The present study aims to optimize precision of PI:C measurements by automating a dual-label trefoil-type time-resolved fluorescence immunoassay (TT-TRFIA), and to compare its diagnostic performance for predicting type 1 diabetes with that of clamp-derived C-peptide release. Between-day imprecision (n = 20) and split-sample analysis (n = 95) were used to compare TT-TRFIA (AutoDelfia, Perkin-Elmer) with separate methods for proinsulin (in-house TRFIA) and C-peptide (Elecsys, Roche). High-risk multiple autoantibody-positive first-degree relatives (n = 49; age 5–39) were tested for fasting PI:C, HOMA2-IR and hyperglycemic clamp and followed for 20–57 months (interquartile range). TT-TRFIA values for proinsulin, C-peptide and PI:C correlated significantly (r2 = 0.96–0.99; Ps = -0.596; P<0.001) with first-phase C-peptide release during clamp (also with second phase release, only available for age 12–39 years; n = 31), but only after normalization for HOMA2-IR. In ROC- and Cox regression analysis, HOMA2-IR-corrected PI:C predicted 2-year progression to diabetes equally well as clamp-derived C-peptide release. The reproducibility of PI:C benefits from the automated simultaneous determination of both hormones. HOMA2-IR-corrected PI:C may serve as a minimally invasive alternative to the more tedious hyperglycemic clamp test.